Testosterone Litigation Federal Status Conference in February #Testosterone / #AndroGel / #Testim / #Axiron

Testosterone Lawsuits

A federal litigation that includes hundreds of testosterone lawsuits is looking ahead to its next status conference, which is scheduled to take place February 13, 2015 at 1:30 p.m.

Plaintiffs in these cases allege serious cardiovascular side effects due to their use of the medications. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545). The litigation is steadily moving forward in the U.S. District Court, Northern District of Illinois, and in February will conference over matters related to testosterone lawsuits concerning AndroGel, Testim, Axiron and other prescription therapy hormone treatments.

According to court documents, the testosterone litigation has continued to grow since January 31, 2014, when the U.S. Food and Drug Administration (FDA) issued a public health alert that warned about the potential for low testosterone medications to cause strokes, heart attacks, deep vein thrombosis, pulmonary embolism and other serious cardiovascular problems.

Nearly a year later, a growing number of plaintiffs whose lawsuits involve AndroGel, Testim, Axiron and other products, accuse drug manufacturers of failing to adequately warn about their association with life-threatening heart complications. They further accuse the companies of concealing information about these side effects, and claim that misleading marketing claims about testosterone products drove healthy men to take them.

Men who allege serious cardiovascular side effects due to their use of prescription treatments may be eligible to receive compensation for injury-related damages. If you’ve received testosterone therapy or treatment, contact The Ahearne Law Firm today for a free consultation and case evaluation at (845) 763-4100.